دورية أكاديمية
The potential neuroprotective effects of cannabinoids against paclitaxel-induced peripheral neuropathy: in vitro study on neurite outgrowth.
| العنوان: | The potential neuroprotective effects of cannabinoids against paclitaxel-induced peripheral neuropathy: in vitro study on neurite outgrowth. |
|---|---|
| المؤلفون: | Creanga-Murariu I; Advanced Research and Development Center for Experimental Medicine (CEMEX), Iasi, Romania.; Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.; Oncology Department, Regional Institute of Oncology, Iasi, Romania., Filipiuc LE; Advanced Research and Development Center for Experimental Medicine (CEMEX), Iasi, Romania.; Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania., Gogu MR; Advanced Research and Development Center for Experimental Medicine (CEMEX), Iasi, Romania., Ciorpac M; Advanced Research and Development Center for Experimental Medicine (CEMEX), Iasi, Romania., Cumpat CM; Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.; Clinical Rehabilitation Hospital, Cardiovascular and Respiratory Rehabilitation Clinic, Iasi, Romania., Tamba BI; Advanced Research and Development Center for Experimental Medicine (CEMEX), Iasi, Romania.; Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania., Alexa-Stratulat T; Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.; Oncology Department, Regional Institute of Oncology, Iasi, Romania. |
| المصدر: | Frontiers in pharmacology [Front Pharmacol] 2024 Jun 12; Vol. 15, pp. 1395951. Date of Electronic Publication: 2024 Jun 12 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Media] |
| مستخلص: | Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a shared burden for 68.1% of oncological patients undergoing chemotherapy with Paclitaxel (PTX). The symptoms are intense and troublesome, patients reporting paresthesia, loss of sensation, and dysesthetic pain. While current medications focus on decreasing the symptom intensity, often ineffective, no medication is yet recommended by the guidelines for the prevention of CIPN. Cannabinoids are an attractive option, as their neuroprotective features have already been demonstrated in neuropathies with other etiologies, by offering the peripheral neurons protection against toxic effects, which promotes analgesia. Methods: We aim to screen several new cannabinoids for their potential use as neuroprotective agents for CIPN by investigating the cellular toxicity profile and by assessing the potential neuroprotective features against PTX using a primary dorsal root ganglion neuronal culture. Results: Our study showed that synthetic cannabinoids JWH-007, AM-694 and MAB-CHMINACA and phytocannabinoids Cannabixir ® Medium dried flowers (NC1) and Cannabixir ® THC full extract (NC2) preserve the viability of fibroblasts and primary cultured neurons, in most of the tested dosages and time-points. The combination between the cannabinoids and PTX conducted to a cell viability of 70%-89% compared to 40% when PTX was administered alone for 48 h. When assessing the efficacy for neuroprotection, the combination between cannabinoids and PTX led to better preservation of neurite length at all tested time-points compared to controls, highly drug and exposure-time dependent. By comparison, the combination of the cannabinoids and PTX administered for 24 h conducted to axonal shortening between 23% and 44%, as opposed to PTX only, which shortened the axons by 63% compared to their baseline values. Discussion and Conclusion: Cannabinoids could be potential new candidates for the treatment of paclitaxel-induced peripheral neuropathy; however, our findings need to be followed by additional tests to understand the exact mechanism of action, which would support the translation of the cannabinoids in the oncological clinical practice. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Creanga-Murariu, Filipiuc, Gogu, Ciorpac, Cumpat, Tamba and Alexa-Stratulat.) |
| References: | Curr Drug Targets CNS Neurol Disord. 2005 Dec;4(6):677-84. (PMID: 16375685) Biochem Pharmacol. 2021 Jun;188:114520. (PMID: 33741328) Toxicology. 2012 Jan 27;291(1-3):1-9. (PMID: 22079234) Med Hypotheses. 2004;63(2):187-92. (PMID: 15236773) Pain Med. 2014 Oct;15(10):1669-85. (PMID: 24641192) Front Cell Neurosci. 2019 Dec 20;13:566. (PMID: 31920563) Pharmacol Ther. 1984;25(1):83-125. (PMID: 6149569) Front Physiol. 2021 Nov 30;12:785176. (PMID: 34916962) Toxics. 2023 Jul 04;11(7):. (PMID: 37505547) Pediatr Res. 2006 Aug;60(2):169-73. (PMID: 16864698) Curr Med Chem. 2010;17(14):1382-93. (PMID: 20166926) Braz J Psychiatry. 2006 Jun;28(2):153-7. (PMID: 16810401) Toxicol Sci. 2017 Mar 1;156(1):275-288. (PMID: 28115644) Biol Psychiatry. 2015 Mar 1;77(5):475-87. (PMID: 24853387) Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10529-33. (PMID: 12917492) Neurotherapeutics. 2009 Oct;6(4):648-62. (PMID: 19789070) Curr Pharm Des. 2008;14(23):2279-88. (PMID: 18781978) Anesth Analg. 2011 Oct;113(4):947-50. (PMID: 21737705) J Pain Symptom Manage. 2014 Jan;47(1):166-73. (PMID: 23742737) J Clin Med. 2019 Jul 08;8(7):. (PMID: 31288397) J Biol Chem. 2002 Feb 22;277(8):6504-10. (PMID: 11724773) Br J Pharmacol. 2014 Feb;171(3):636-45. (PMID: 24117398) Life Sci. 2006 Jan 2;78(6):549-63. (PMID: 16109430) Eur J Pharmacol. 1998 Jul 17;353(1):23-31. (PMID: 9721036) Trends Pharmacol Sci. 2000 Jun;21(6):218-24. (PMID: 10838609) Science. 2001 Mar 30;291(5513):2530-1. (PMID: 11286259) Int J Mol Med. 2018 Aug;42(2):919-925. (PMID: 29786105) Tetrahedron. 1963 Dec;19(12):2073-8. (PMID: 5879214) Biomed Pharmacother. 2022 Mar;147:112671. (PMID: 35104697) Exp Neurol. 2020 Feb;324:113121. (PMID: 31758983) Cancer. 2019 Jul 1;125(13):2242-2251. (PMID: 31006849) Neuropathol Appl Neurobiol. 2013 Jun;39(4):362-76. (PMID: 22845867) Circ Res. 2000 Aug 18;87(4):323-7. (PMID: 10948067) Anticancer Res. 2006 Mar-Apr;26(2A):1065-70. (PMID: 16619507) Pharmaceutics. 2021 Nov 01;13(11):. (PMID: 34834237) J Clin Oncol. 2020 Oct 1;38(28):3325-3348. (PMID: 32663120) Front Pharmacol. 2023 Jul 13;14:1211506. (PMID: 37521486) J Undergrad Neurosci Educ. 2018 Jun 15;16(2):A186-A194. (PMID: 30057501) Behav Pharmacol. 2011 Sep;22(5-6):607-16. (PMID: 21610490) Neurology. 1994 Mar;44(3 Pt 1):488-94. (PMID: 8145920) Nature. 2001 Oct 4;413(6855):527-31. (PMID: 11586361) Brain. 2021 Jul 28;144(6):1727-1737. (PMID: 33734317) Mol Pharmacol. 2015 Jul;88(1):64-74. (PMID: 25904556) Curr Rheumatol Rep. 2017 Oct 5;19(11):67. (PMID: 28983880) Trends Mol Med. 2002 Feb;8(2):58-61. (PMID: 11815270) Biomolecules. 2021 May 20;11(5):. (PMID: 34065479) Clin Breast Cancer. 2011 Apr;11(2):73-81. (PMID: 21569993) PLoS One. 2018 Sep 10;13(9):e0203793. (PMID: 30199551) CNS Neurol Disord Drug Targets. 2009 Dec;8(6):403-21. (PMID: 19839937) Can J Physiol Pharmacol. 1976 Aug;54(4):541-5. (PMID: 974881) Br J Pharmacol. 2003 Oct;140(3):439-40. (PMID: 14522839) J Surg Res. 2009 Jul;155(1):40-7. (PMID: 19394652) Neuropharmacology. 2014 Jan;76 Pt A:175-83. (PMID: 23978385) Expert Opin Ther Targets. 2017 Jul;21(7):695-703. (PMID: 28480765) J Neurosci. 2005 Feb 23;25(8):1904-13. (PMID: 15728830) Ann Oncol. 2020 Oct;31(10):1306-1319. (PMID: 32739407) Pain. 2021 Jul 1;162(Suppl 1):S5-S25. (PMID: 33729211) Oncol Ther. 2021 Dec;9(2):385-450. (PMID: 34655433) Pain. 2014 Dec;155(12):2461-2470. (PMID: 25261162) J Cannabis Res. 2022 Jun 16;4(1):33. (PMID: 35710586) J Neurosci. 2001 Sep 1;21(17):6475-9. (PMID: 11517236) Plants (Basel). 2021 Sep 03;10(9):. (PMID: 34579367) Brain Res. 2000 Sep 22;877(2):407-10. (PMID: 10986361) J Neurosci. 2012 May 16;32(20):7091-101. (PMID: 22593077) Int J Mol Sci. 2019 Mar 22;20(6):. (PMID: 30909387) Exp Neurol. 2020 Apr;326:113140. (PMID: 31812556) Mol Pain. 2014 Apr 18;10:27. (PMID: 24742127) Br J Pharmacol. 2007 Nov;152(5):765-77. (PMID: 17572696) Pharmacol Biochem Behav. 2013 Apr;105:205-12. (PMID: 23454533) Medicina (Kaunas). 2020 Jan 09;56(1):. (PMID: 31936616) Front Pharmacol. 2018 Aug 13;9:889. (PMID: 30150937) Semin Oncol. 2006 Feb;33(1):15-49. (PMID: 16473643) Mol Cancer Ther. 2014 Dec;13(12):2955-67. (PMID: 25398831) FEBS J. 2013 May;280(9):1918-43. (PMID: 23551849) Toxics. 2021 Sep 22;9(10):. (PMID: 34678925) Pain Res Manag. 2018 Jul 25;2018:5234943. (PMID: 30147813) Cancer. 2017 Nov 15;123(22):4488-4497. (PMID: 28944449) Breast Care (Basel). 2019 Apr;14(2):79-84. (PMID: 31798378) Int Rev Neurobiol. 2019;146:229-257. (PMID: 31349929) Molecules. 2021 Oct 08;26(19):. (PMID: 34641624) Biomolecules. 2022 Dec 14;12(12):. (PMID: 36551301) Drugs. 2019 Jun;79(9):969-995. (PMID: 31127530) Neurotoxicology. 2000 Jun;21(3):389-93. (PMID: 10894128) Eur J Pharmacol. 2008 Mar 31;583(1):56-61. (PMID: 18279850) |
| فهرسة مساهمة: | Keywords: CBD; THC; antalgic; cannabis; cellular model; chemotherapy; neuropathic pain; palliative care |
| تواريخ الأحداث: | Date Created: 20240627 Latest Revision: 20240628 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC11199736 |
| DOI: | 10.3389/fphar.2024.1395951 |
| PMID: | 38933665 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2024.1395951 |